LAB B Stock Financial Analysis - Genomma Lab Internacional, S.A.B. de C.V. (BMV) Stock

Overview

Genomma Lab Internacional is a Mexico-based multinational pharmaceutical and personal care products company. Operating primarily in the pharmaceutical sector, it is renowned for developing, selling, and marketing various products for various health and personal care needs. Its portfolio includes over-the-counter drugs and personal care products under over 80 brands. The company has a significant presence in international markets across 18 countries, including the United States, where it launched several key products in 2020. Genomma Lab Internacional's continual innovation, strong brand portfolio, and strategic expansion efforts underscore its position as a leading global pharmaceutical and personal care industry player.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for Genomma Lab Internacional, S.A.B. de C.V. as of June 30, 2025 is 18,840.85 MM.
The operating income for Genomma Lab Internacional, S.A.B. de C.V. as of June 30, 2025 is 4,064.18 MM.
The net income for Genomma Lab Internacional, S.A.B. de C.V. as of June 30, 2025 is 1,941.05 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30	18,840.85	4,064.18	1,941.05
2025-03-31	18,815.91	4,016.82	2,217.72
2024-12-31	18,606.90	3,913.45	2,091.11
2024-09-30	17,466.48	3,666.40	1,602.65
2024-06-30	16,767.21	3,372.76	1,313.26
2024-03-31	16,486.22	3,260.54	1,099.02
2023-12-31	16,467.13	3,207.09	1,084.91
2023-09-30	17,074.20	3,329.70	1,392.07
2023-06-30	17,030.20	3,303.37	1,420.67
2023-03-31	16,983.33	3,272.13	1,408.02
2022-12-31	16,819.91	3,243.53	1,366.45
2022-09-30	16,777.80	3,318.57	1,359.25
2022-06-30	16,412.49	3,242.59	1,353.18
2022-03-31	15,954.22	3,144.76	1,327.63
2021-12-31	15,487.06	3,056.33	1,307.87
2021-09-30	14,868.32	2,894.16	1,351.74
2021-06-30	14,312.30	2,842.37	1,367.67
2021-03-31	14,083.26	2,815.23	1,416.16
2020-12-31	13,870.15	2,769.01	1,403.50
2020-09-30	13,619.04	2,607.11	1,179.23

Income Statement: EPS

The earnings per share basic for Genomma Lab Internacional, S.A.B. de C.V. as of June 30, 2025 is 1.94.
The earnings per share diluted for Genomma Lab Internacional, S.A.B. de C.V. as of June 30, 2025 is 1.94.

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30	1.94	1.94
2025-03-31	2.24	2.24
2024-12-31	2.14
2024-09-30	1.67	1.67
2024-06-30	1.39	1.39
2024-03-31	1.16	1.16
2023-12-31	1.13
2023-09-30	1.44	1.44
2023-06-30	1.46	1.46
2023-03-31	1.43	1.43
2022-12-31	1.38
2022-09-30	1.37	1.37
2022-06-30	1.36	1.36
2022-03-31	1.32	1.32
2021-12-31	1.30
2021-09-30	1.34	1.34
2021-06-30	1.35	1.35
2021-03-31	1.40	1.40
2020-12-31	1.39
2020-09-30	1.16	1.16

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Genomma Lab Internacional, S.A.B. de C.V. as of June 30, 2025 is 3,106.61 MM.
The cash from investing activities for Genomma Lab Internacional, S.A.B. de C.V. as of June 30, 2025 is -799.89 MM.
The cash from financing activities for Genomma Lab Internacional, S.A.B. de C.V. as of June 30, 2025 is -759.25 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	3,106.61	-799.89	-759.25
2025-03-31	3,009.16	-776.30	-1,200.66
2024-12-31	3,033.72	-731.97	-1,591.04
2024-09-30	2,568.53	-1,017.83	-1,650.52
2024-06-30	1,766.90	-381.07	-1,599.22
2024-03-31	1,802.53	-280.38	-1,590.19
2023-12-31	2,247.01	-302.21	-1,676.82
2023-09-30	1,775.44	-133.28	-720.22
2023-06-30	1,519.34	-392.37	-1,023.94
2023-03-31	1,347.37	-251.96	-1,161.77
2022-12-31	2,054.79	-488.22	-1,362.40
2022-09-30	2,409.16	-441.68	-2,494.20
2022-06-30	2,558.78	-551.30	-2,025.21
2022-03-31	2,326.64	-651.61	-1,907.59
2021-12-31	1,468.35	-765.62	-1,469.24
2021-09-30	1,494.93	-683.65	-528.45
2021-06-30	1,282.75	-728.36	-232.61
2021-03-31	1,316.07	-719.57	-24.64
2020-12-31	1,714.53	-663.65	189.85
2020-09-30	1,267.77	-806.26	-30.93

Valuation Metrics : PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30

Management Effectiveness

The roa for Genomma Lab Internacional, S.A.B. de C.V. as of June 30, 2025 is 0.08.
The roe for Genomma Lab Internacional, S.A.B. de C.V. as of June 30, 2025 is 0.18.
The roic for Genomma Lab Internacional, S.A.B. de C.V. as of June 30, 2025 is 0.08.
The croic for Genomma Lab Internacional, S.A.B. de C.V. as of June 30, 2025 is 0.07.
The ocroic for Genomma Lab Internacional, S.A.B. de C.V. as of June 30, 2025 is 0.10.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	0.08	0.18	0.08	0.07	0.10
2025-03-31	0.08	0.18	0.08	0.07	0.10
2024-12-31	0.08	0.18	0.08	0.07	0.10
2024-09-30	0.08	0.18	0.08	0.07	0.10
2024-06-30	0.08	0.18	0.08	0.07	0.10
2024-03-31	0.08	0.18	0.08	0.07	0.10
2023-12-31	0.08	0.18	0.08	0.07	0.10
2023-09-30	0.08	0.18	0.08	0.07	0.10
2023-06-30	0.08	0.18	0.08	0.07	0.10
2023-03-31	0.08	0.18	0.08	0.07	0.10
2022-12-31	0.08	0.18	0.08	0.07	0.10
2022-09-30	0.08	0.18	0.08	0.07	0.10
2022-06-30	0.08	0.18	0.08	0.07	0.10
2022-03-31	0.08	0.18	0.08	0.07	0.10
2021-12-31	0.08	0.18	0.08	0.07	0.10
2021-09-30	0.08	0.18	0.08	0.07	0.10
2021-06-30	0.08	0.18	0.08	0.07	0.10
2021-03-31	0.08	0.18	0.08	0.07	0.10
2020-12-31	0.08	0.18	0.08	0.07	0.10
2020-09-30	0.06	0.15	0.07	0.03	0.08

Gross Margins

The gross margin for Genomma Lab Internacional, S.A.B. de C.V. as of June 30, 2025 is 0.62.
The net margin for Genomma Lab Internacional, S.A.B. de C.V. as of June 30, 2025 is 0.11.
The operating margin for Genomma Lab Internacional, S.A.B. de C.V. as of June 30, 2025 is 0.20.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30	0.62	0.11	0.20
2025-03-31	0.62	0.11	0.20
2024-12-31	0.62	0.11	0.20
2024-09-30	0.62	0.11	0.20
2024-06-30	0.62	0.11	0.20
2024-03-31	0.62	0.11	0.20
2023-12-31	0.62	0.11	0.20
2023-09-30	0.62	0.11	0.20
2023-06-30	0.62	0.11	0.20
2023-03-31	0.62	0.11	0.20
2022-12-31	0.62	0.11	0.20
2022-09-30	0.62	0.11	0.20
2022-06-30	0.62	0.11	0.20
2022-03-31	0.62	0.11	0.20
2021-12-31	0.62	0.11	0.20
2021-09-30	0.62	0.11	0.20
2021-06-30	0.62	0.11	0.20
2021-03-31	0.62	0.11	0.20
2020-12-31	0.62	0.11	0.20
2020-09-30	0.62	0.09	0.19